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for this discrepancy could be the racial differences in the
occurrences of BRAF mutation.
The most impressive examples of recent cancer therapies used
protein kinase inhibitors such as Imanitib (Gleevec).1 Since the
RAS-RAF-MEK-ERK-MAP kinase pathway is activated by protein
kinase, therapies that target this signaling pathway would
therefore be very valuable in treating tumors that have activating
mutations of BRAF. In this respect, the present study may
provide the possibility of therapy targeting mutated BRAF in
acute leukemias.
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TO THE EDITOR
The long-term prognosis of adult lymphoblastic leukemia (ALL)
is still disappointing, and only 20–35% of adult patients are
cured by chemotherapy. Little is known as to the proliferative
activity of ALL in adult patients, and classical kinetic parameters
were inconclusive when used as prognosis predictors.
The analysis of the argyrophilic proteins associated with the
nucleolar organizer regions (NORs), loops of DNA that
transcribe to ribosomal RNA, is a technique (AgNOR method)
to assess cell proliferation that can be easily performed in
routinely fixed and paraffin-embedded tissues.1 AgNOR quan-
tity is strictly related to the rapidity of cell proliferation: the
higher the AgNOR quantity, the shorter the tumor cell doubling
time.2 We have previously demonstrated the prognostic value of
AgNOR analysis on bone marrow (BM) biopsies of patients with
adult AML.3 Only two studies have reported an association
between poor prognosis and a large AgNOR area4 or number5 in
children with ALL.
In the present study, we analyzed the AgNOR expression on
BM biopsies from 36 adult patients with ALL at diagnosis, to
investigate if the rapidity of blast cell proliferation was
associated to clinico-pathologic features and prognosis of the
disease.
A total of 36 consecutive adult patients with newly diagnosed
ALL and available BM biopsy, admitted to the Division of
Haematology, S. Giovanni Hospital, Turin, Italy, between 1994
and 2001, were included in the study. There were 19 female and
17 male patients (mean age, 35.5 years; range, 16–65).
According to the French–American–British (FAB) criteria, nine
were L1 and 27 L2 ALL; 31 were B-ALL and five T-ALL. In all, 10
patients had a normal karyotype, nine had t(9:22) translocation
(Philadelphia chromosome-positive (Phþ )) and five miscella-
neous cytogenetic abnormalities. By reverse transcription-
polymerase chain reaction (RT-PCR) technique, 20 cases
showed bcr/abl gene rearrangement (BCR/ABLþ ).
All patients were treated according to the multicenter protocol
GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto)
ALL 0496.6 Induction therapy consisted of vincristine (1.4 mg/
m2 on days 1–8–15–22–36), three cycles of daunorubicin
(30 mg/m2/day for 3 days starting on days 1–22–36), L-
asparaginase (6000 IU/m2 every other day from day 10 to 30)
and prednisone (30 mg/m2/day for 30 days). Patients in complete
remission were treated with one cycle (two cycles in patients
less than 50 years old) with high-dose Ara-C (2 g/m2 every 12 h
for four doses), etoposide (150 mg/m2/day for 3 days) and
Cyclophosphamide (300 mg/m2 every 12 h for six doses). The
patients received central nervous system prophylaxis with
intrathecal methotrexate and cranial radiation. Maintenance
treatment with 6-mercaptopurine and methotrexate with
periodic cycles of reinduction was continued for 3 years.
Patients with Phþ leukemia received a consolidation with
HAM chemotherapy followed by an allogeneic bone marrow
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transplantation or, in the absence of a suitable donor, an
autologous stem cell transplantation. The follow-up was
complete on 31 May 2002.
AgNORs were detected according to the method of Ploton
et al1 on BM biopsies taken during initial investigation,
decalcified and embedded in paraffin. AgNORs were counted
as previously reported3 by two pathologists (AP and LC), who
independently examined at least 100 blast cells in each case,
using a  100 oil immersion lens. The mean number of
AgNORs per nucleus was calculated in each case. One-way
analysis of the variance, Yates’ corrected w2 test, uni- and multi-
variate survival analysis were used for statistical evaluation.
The mean AgNOR for the whole series was 3.1 (median, 3.04;
s.d.¼ 0.71; range, 2.04–4.66). It was higher in Phþ ALL (3.47)
than in ALL with normal karyotype (3) or miscellaneous
cytogenetic abnormalities (2.51; P¼ 0.03) (Figures 1 and 2).
AgNOR count also tended to be higher in BCR/ABLþ cases
(3.2) than in ALL without bcr/abl rearrangement (2.87; P¼ 0.1).
Complete remission (CR) was reached in 18/22 (81.8%) cases
with AgNOR count less than 3.1, but in only 8/14 (57.1%) cases
with a greater count (P¼ 0.2). At the time of analysis, 27 patients
(75%) had died of the disease and nine (25%) were alive,
without evidence of disease (censored). The mean follow-up for
the whole series was 19.3 months (median,14; range, 0.6–89).
The mean follow-up duration for censored patients in contin-
uous CR was 35.22 months (median, 16; range, 7–89). The
median overall survival (OS) duration for the whole series was
15.5 months. An association was found between AgNOR counts
and OS: using the mean AgNOR count as a cutoff, the median
OS was 17 months for patients withp3.1 AgNOR/blast cell and
only 10.2 months for those with a higher count (P¼ 0.03). At
multivariate analysis, when CR was excluded from the analysis,
AgNOR counts emerged as the only significant variable (w2,
3.59; P¼ 0.05; risk ratio, 2.21). The median disease-free survival
(DFS) duration for the 26 patients who achieved CR was 11.3
months. It was 13.7 months for patients withp3.1 AgNOR/blast
cell, but only 4.2 months for those with a higher count
(P¼ 0.007) (Figure 3). At multivariate analysis, AgNOR count
was the only significant prognostic factor for remission duration
(w2, 7.90; P¼ 0.005; risk ratio, 8.36).
Our results show a significant association between a rapid
proliferative activity of marrow blast cells, as indicated by high
AgNOR counts, and a shorter OS and DFS in adult ALL, in
agreement with a few reports in childhood ALL.4,5 To the best of
our knowledge, there is no mention in the literature as to the
correlation between AgNORs and prognosis in adult ALL. These
findings are rather different from those previously reported in a
series of adult AML in which we showed that AML patients
with high AgNOR counts had a longer OS and DFS.3 The
discrepancies may depend on the different kinetic character-
istics of ALL and AML blast cells: the mean AgNOR count in ALL
(3.1þ 0.71) is significantly lower (Po0.0001) than in AML
(6.671.35).3 AgNOR quantity reflects the rapidity of cell
doubling time;2 it is likely that leukemic clones of AML, which
have a short doubling time (as assessed by the high AgNOR
value), are very sensitive to the intensive induction chemother-
apy, resulting in a high CR rate and/or in a very low minimal
residual disease with survival advantage for patients. On the
contrary, the doubling time of ALL blasts is long, when
compared to AML; therefore, a larger number of quiescent
leukemic blasts would escape the intensive chemotherapy
currently used in ALL, resulting in the persistence of resistant
clones. Moreover, the length of remission in ALL patients
achieving CR not only depends on the size of the minimal
residual disease but also on the rapidity of proliferation of the
resistant clones. Indeed, the median DFS in our series was 13.7
months for patients with low AgNOR counts, but only 4.2
months for those with higher counts (P¼ 0.007). Therefore, it is
likely that a more rapid proliferation of the residual clones (as
indicated by their relatively higher AgNOR counts) would result
Figure 1 Phþ acute lymphoblastic leukemia. Blast cells show
numerous small-sized AgNORs scattered within the nucleus (AgNOR
staining; original magnification 400; inset:1000).
Figure 2 Adult ALL showing blast cells with few small AgNORs
within the nucleus (AgNOR staining; original magnification400;
inset:1000).
Figure 3 Actuarial probability of DFS for adult patients with ALL
categorized according to the mean AgNOR counts.
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in a more rapid relapse and shorter OS and DFS. The kinetic
characteristics of adult ALL seem to be rather similar to NHL,
since NHL with high AgNOR quantity have a poorer prognosis
than NHL with low AgNOR quantity.7 Interestingly, in the
present series, AgNOR count was significantly higher in Phþ
ALL than in cases with different karyotypes, and tended to be
higher in BCR-ABLþ ALL. It is well known that adult patients
with Phþ ALL have a significantly lower probability of
continuous CR, as well as a shorter OS and DFS, than do ALL
patients with normal karyotype or miscellaneous cytogenetic
abnormalities.8 Therefore, the worse prognosis for Phþ ALL
could also depend on the shorter doubling time of blast cells, as
assessed by their relatively high AgNOR counts.
We are aware that the number of cases in our study is
relatively small, so that any conclusion should be taken with
caution; however, this preliminary study clearly indicates that a
high proliferative activity, in particular the rapidity of blast cell
duplication, as assessed by AgNOR counts, is associated with a
worse prognosis in adult ALL patients treated with the same
protocol. We believe that the evaluation of the leukemic blast
proliferative activity on BM biopsies, together with the
traditional morphologic, immunophenotypic, cytogenetic and
molecular studies, could well be a further refinement of the
prognostic assessment of adult patients with ALL.
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TO THE EDITOR
We describe the detection of a single base pair insertion in the
HLA-An2402 allele in the blast cells of a patient with B-cell
acute lymphoblastic leukemia (B-ALL). This mutation resulted in
the loss of expression of HLA-An2402 on the blast cells. The
mutation was not present in the nonleukemia cells on which
HLA-An2402 was normally expressed. The mutation was
detected following HLA typing by DNA sequencing during
routine workup for bone marrow transplantation.
There is considerable evidence to suggest that proliferation of
tumor cells is controlled in some part by the immune system.
This includes tumor cell killing by cytotoxic T lymphocytes
following the presentation of tumor-specific peptide by tumor
cell HLA.1 Thus, the loss of expression of HLA molecules on
tumor cells may result in a selective advantage for a tumor cell
clone and have adverse effects on the course of the disease and
efficacy of T–cell-based immunotherapy. The loss or down-
regulation of HLA on the surface of tumor cells has been
reported in many solid organ tumors. However, the loss of HLA
in leukemia and lymphoma has been less frequently reported.
The most frequently observed defect resulting in the loss of
HLA is the deletion of sections of varying size of the major
histocompatibility complex (MHC) from one chromosome.
The loss of a single HLA allele may be sufficient to enable the
tumor cell to avoid immune surveillance if this allele presents
tumor-specific peptide. However, such loss may go undetected
by most molecular HLA typing techniques if the loss is the result
of a single base mutation.
In addition, phenotypic detection of allele loss may go
undetected unless allele-specific monoclonal antibodies are
used, as single allele loss may not result in a quantitative loss of
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